REGENERON PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
REGENERON PHARMACEUTICALS, INC. (REGN) had Debt Securities, Available-for-sale, Amortized Cost of $15.22 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $15.22B.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $15.52B.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $15.62B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $15.43B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $15.22B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $15.52B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $15.62B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $15.43B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $13.98B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $13.26B 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $14.34B 10-K · filed 2026-02-04 | |
| 2024-09-30 | $14.89B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $14.52B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $14.21B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $12.64B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $12.84B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $12.54B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $10.28B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $10.32B 10-K · filed 2024-02-05 | |
| 2022-09-30 | $8.72B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $9.99B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $9.97B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $8.43B 10-K · filed 2023-02-06 | |
| 2021-09-30 | $6.60B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $4.32B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $4.58B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $3.65B 10-K · filed 2022-02-07 | |
| 2020-09-30 | $3.51B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $2.89B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $4.48B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $4.21B 10-K · filed 2021-02-08 | |
| 2019-09-30 | $4.15B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $4.07B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $3.73B 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $3.03B 10-K · filed 2020-02-07 | |
| 2018-09-30 | $2.85B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.74B 10-Q · filed 2018-08-02 | |
| 2017-12-31 | $2.03B 10-K · filed 2019-02-07 | $2.03B 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |